Manas D, Bell JK, Mealing S, et al. - The cost-effectiveness of TheraSphere vs other embolic treatments was evaluated in a population with early to intermediate stage hepatocellular carcinoma (HCC) who are unresectable at presentation and are eligible for transarterial embolization (TAE), conventional transarterial chemoembolization (cTACE) or drug-eluting bead TACE (DEB-TACE). Researchers constructed a Markov model using a UK National Health Service (NHS) perspective, a 20-year time horizon, and 4-week cycles. Following were the eight included health states: ‘watch and wait’, ‘transplantation’ (pre-, post and post (No HCC)), ‘resection’, “no HCC other”, ‘pharmacological management’ and ‘death’. Relative to all other treatments, TheraSphere was predictive of gaining 0.7 additional QALYs. For TheraSphere, the base case ICERs of £17,300, £17,279 and £23,020 per QALY gained were reported compared with TAE, cTACE and DEB-TACE, respectively. In the TheraSphere cohort, 87% more patients were predicted to attain downstaging compared with all other treatment options. These findings suggest that for patients with early to intermediate stage HCC, TheraSphere treatment is a potentially cost-effective option.